The clinical guys can reply to this better but if you read the whole thing, it is open label and 28 days. The March/22 completion is probably longer term measuring of results and reactions with SOC etc. The effacay results should be know after 28 days and if good, could proceed. What I am not sure of is whether this is notifying of the US portion as the location is stated as San Francisco or just the Canadian/Brazil portion and San Francisco is just because Mike Sweeney is the lead and he is there. It appears like it is the US portion. Maybe the Health Canada letter was enough to proceed with the Canada/Brazil portion and it isn't being listed on clinicaltrials.gov due to the US trial being listed there. Any help from the clinical experienced would be welcome.

I don't often give DM any credit but he might not have been wrong with his statement of being on clinicaltrials.gov soon. It was submitted on May 5th and he stated that on the 12th so it might have been out of RVX hands.